HIV

Hope for people co-infected with visceral leishmaniasis and HIV

Today, the World Health Organization (WHO) has released its guidelines for the treatment of people co-infected with visceral leishmaniasis and HIV, to recommend better treatments based on the results of two studies conducted by the Drugs for Neglected Diseases initiative (DNDi), Médecins Sans Frontières (MSF) and their partners in Ethiopia and India. In Ethiopia, the new treatment strategy was shown to have an 88% efficacy rate at the end of therapy (after 58 days), whereas the efficacy

New drug outperforms PreP in preventing HIV among African women

The Joint United Nations Programme on HIV/AIDS (UNAIDS) has announced that it is strongly encouraged by new study results showing that the antiretroviral medicine cabotegravir, which is administered by injection every two months, prevents HIV among women. The study shows that the long-acting injections among women in sub-Saharan Africa were 89% more efficient in preventing HIV compared to daily tablets of pre-exposure prophylaxis (PrEP). “These results are hugely significant. UNAIDS has long been calling for additional, acceptable and effective HIV prevention options